» Articles » PMID: 35676850

Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review

Overview
Journal Curr Drug Metab
Specialties Chemistry
Endocrinology
Date 2022 Jun 9
PMID 35676850
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is the most prevalent cancer in women around the world, having a sudden spread nowadays because of the poor sedentary lifestyle of people. Comprising several subtypes, one of the most dangerous and aggressive ones is triple-negative breast cancer or TNBC. Even though conventional surgical approaches like single and double mastectomy and preventive chemotherapeutic approaches are available, they are not selective to cancer cells and are only for symptomatic treatment. A new branch called nanotechnology has emerged in the last few decades that offers various novel characteristics, such as size in nanometric scale, enhanced adherence to multiple targeting moieties, active and passive targeting, controlled release, and site-specific targeting. Among various nanotherapeutic approaches like dendrimers, lipid-structured nanocarriers, carbon nanotubes, etc., nanoparticle targeted therapeutics can be termed the best among all for their specific cytotoxicity to cancer cells and increased bioavailability to a target site. This review focuses on the types and molecular pathways involving TNBC, existing treatment strategies, various nanotechnological approaches like exosomes, carbon nanotubes, dendrimers, lipid, and carbon-based nanocarriers, and especially various nanoparticles (NPs) like polymeric, photodynamic, peptide conjugated, antibody-conjugated, metallic, inorganic, natural product capped, and CRISPR based nanoparticles already approved for treatment or are under clinical and pre-clinical trials for TNBC.

Citing Articles

Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.

Subhan M, Torchilin V Bioengineering (Basel). 2024; 11(8).

PMID: 39199788 PMC: 11351222. DOI: 10.3390/bioengineering11080830.

References
1.
Manjunath M, Choudhary B . Triple-negative breast cancer: A run-through of features, classification and current therapies. Oncol Lett. 2021; 22(1):512. PMC: 8114477. DOI: 10.3892/ol.2021.12773. View

2.
Shafi S, Khan S, Hoda F, Fayaz F, Singh A, Ahmed Khan M . Decoding Novel Mechanisms and Emerging Therapeutic Strategies in Breast Cancer Resistance. Curr Drug Metab. 2020; 21(3):199-210. DOI: 10.2174/1389200221666200303124946. View

3.
Zucca-Matthes G, Urban C, Vallejo A . Anatomy of the nipple and breast ducts. Gland Surg. 2016; 5(1):32-6. PMC: 4716863. DOI: 10.3978/j.issn.2227-684X.2015.05.10. View

4.
Malhotra G, Zhao X, Band H, Band V . Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther. 2010; 10(10):955-60. PMC: 3047091. DOI: 10.4161/cbt.10.10.13879. View

5.
Wu X, Chen G, Qiu J, Lu J, Zhu W, Chen J . Visualization of basement membranes in normal breast and breast cancer tissues using multiphoton microscopy. Oncol Lett. 2016; 11(6):3785-3789. PMC: 4888276. DOI: 10.3892/ol.2016.4472. View